Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 5/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 8/20 | 0.34 |
| ▸ | JAK2 | O60674 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903455 | 0.88 | PDE2A (0.36) | AKT1AKT2PDE2ASSTR4 | |
| SCHEMBL1906606 | 0.86 | AKT1 (0.41) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL1902115 | 0.85 | AKT1 (0.42) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL1534619 | 0.82 | PLA2G2A (0.46) | AKT1AKT2 | |
| SCHEMBL1901791 | 0.82 | PLA2G2A (0.46) | AKT1AKT2 | |
| SCHEMBL1534480 | 0.81 | AKT1 (0.41) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL14118861 | 0.80 | AKT1 (0.44) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL1534644 | 0.80 | AKT1 (0.41) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL1534642 | 0.80 | AKT1 (0.41) | AKT1AKT2PDE2ACNR1CNR2 | |
| SCHEMBL1534821 | 0.80 | AKT1 (0.44) | AKT1AKT2PDE2ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2012-12-06 | — | — | US | disclosed |
| EP-2496566-A1 | AKT / PKB INHIBITORS | Almac Discovery Limited (GB) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011055115-A1 | AKT / PKB INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309739-A1 | AKT / PKB INHIBITORS | AKT1, AKT2, AKT3 | AKT1 1/4885AKT2 2/4885PDE2A 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.